Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Recon: Merck KGaA to exit CDMO business; Karyopharm to sell itself in bankruptcy

3 November 2026 · By · Wire by Fusion42

Published

3 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at raps.org →

◆ Verified

Fusion42 · 3 November 2026 · Fusion42 review

Merck KGaA is divesting its US CDMO (Contract Development and Manufacturing Organization) business to Lonza, and Karyopharm is entering bankruptcy with plans to sell itself.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must prepare for shifts in CDMO partnerships as Merck KGaA exits the US market and Lonza expands. Karyopharm’s bankruptcy signals rising risks for mid-size biotech players and potential opportunities to acquire assets or talent.

◆ Coverage

1 source · 3 Nov 2026

◆ Related on Wire

◆ Topics

Biotechpharmacdmobankruptcymergers-and-acquisitionsbiotech